Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors

Journal of Clinical Oncology

Volumn 18, Issue 3, 2000, Pages 584-590

  Colleoni, Marco ^a   Bonetti, Marco ^a   Coates, Alan S ^a   Castiglione Gertsch, Monica ^a   Gelber, Richard D ^a   Price, Karen ^a   Rudenstam, Carl Magnus ^a   Lindtner, Jurij ^a   Collins, John ^a   Thürlimann, Beat ^a   Holmberg, Stig ^a   Veronesi, Andrea ^a   Marini, Giovanni ^a   Goldhirsch, Aron ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PREDNISONE;

ADULT; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PREMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; TREATMENT OUTCOME;

EID: 0033966381     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.2000.18.3.584     Document Type: Article

References (44)

1. Goldhirsch A, Gelber RD, Davis BW: Adjuvant chemotherapy trials in breast cancer: An appraisal and lessons for patient care outside the trials, in Forbes JF (ed): Breast Disease. Edinburgh, United Kingdom, Churchill Livingstone, 1986, pp 123-138
2. Kinne DW: Primary treatment of breast cancer surgery, in Harris JR, Hellman S, Henderson IC, et al (eds): Breast Diseases (ed 2). Philadelphia, PA, Lippincott, 1991, pp 347-373
3. Bonadonna G, Brusamolino E, Valagussa P, et al: Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 294:405-410, 1976
4. McCulloch P, Choy A: Effect of menstrual phase on surgical treatment of breast cancer. Lancet 344:402-403, 1994
5. Gunduz N, Fisher B, Saffer EA: Effect of surgical removal on the growth and kinetics of residual tumor. Cancer Res 39:3861-3865, 1979
6. Fidler IJ, Ellis LM: The implication of angiogenesis for the biology and therapy of cancer metastasis. Cell 79:185-188, 1994
7. Eggermont AMM, Steller EP, Sugarbaker PH: Laparotomy enhances intraperitoneal tumor growth and abrogates the antitumor effects of interleukin 2 and lymphokine-activated killer cells. Surgery 102:71-78, 1987
8. Ono I, Gunji H, Suda K, et al: Evaluation of cytokines in donor site wound fluid. Scand J Plast Reconstr Surg Hand Surg 28:269-273, 1994
9. McCulloch P, Choy A, Martin L: Association between tumour angiogenesis and tumour cell shedding into effluent venous blood during breast cancer surgery. Lancet 346:1334-1335, 1995
10. Obermair A, Kurz C, Czerwenka C, et al: Microvessel density and vessel invasion in lymph-node negative breast cancer: Effect on recurrence-free survival. Int J Cancer 62:126-131, 1995
11. Toi M, Inada K, Suzuki I, et al: Tumor angiogenesis in breast cancer: Its importance as a prognostic indicator and the association with vascular endothelial growth factor expression. Breast Cancer Res Treat 36:193-204, 1995
12. The Ludwig Breast Cancer Study Group: Combination adjuvant chemotherapy for node-positive breast cancer: Inadequacy of a single perioperative cycle. N Engl J Med 319:677-683, 1988
13. The Ludwig Breast Cancer Study Group: A randomized trial of adjuvant combination chemotherapy with or without prednisone in premenopausal breast cancer patients with metastases in one to three axillary lymph nodes. Cancer Res 45:4454-4459, 1985
14. The Ludwig Breast Cancer Study Group: Chemotherapy with or without oophorectomy in high-risk premenopausal patients with operable breast cancer. J Clin Oncol 3:1059-1067, 1985
15. The International Breast Cancer Study Group: Duration and reintroduction of adjuvant chemotherapy for node-positive premenopausal breast cancer patients. J Clin Oncol 14:1885-1894, 1996
16. Paulsen SM, Pedersen KO: Comparison of histo- and biochemical methods for estrogen and progesterone receptor analysis in primary human breast carcinoma. Eur J Cancer Clin Oncol 21:1331-1336, 1985
17. Zava DT, Wyler-von Ballmoos A, Goldhirsch A, et al: A quality control study to assess the interlaboratory variability of routine estrogen and progesterone receptor assays. Eur J Cancer Clin Oncol 18:713-721, 1982
18. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
19. Cox DR: Regression models and life tables (with discussion). J Royal Stat Soc B 34:187-220, 1972
20. Brooks RJ, Jones SE, Salmon SE, et al: Improved outcome with early treatment in an adjuvant breast cancer program. Proc Am Soc Clin Oncol 2:110, 1983 (abstr C-431)
21. Pronzato P, Campora E, Amoroso D, et al: Impact of administration-related factors on outcome of adjuvant chemotherapy for primary breast cancer. Am J Clin Oncol 12:481-485, 1989
22. Nissen-Meyer R, Kjellgren K, Malmio K, et al: Surgical adjuvant chemotherapy: Results with one short course with cyclophosphamide after mastectomy from breast cancer. Cancer 41:2088-2098, 1978
23. Clahsen PC, van de Velde CJH, Goldhirsch A, et al: Overview of randomized perioperative polychemotherapy trials in women with early stage breast cancer. J Clin Oncol 15:2525-2535, 1997
24. Fisher B, Slack N, Katrych D, et al: Ten-year follow-up results of patients with carcinoma of the breast in a co-operative clinical trial evaluating surgical adjuvant chemotherapy. Surg Gynecol Obstet 140:528-534, 1975
25. Sertoli MR, Bruzzi P, Pronzato P, et al: Randomized cooperative study of perioperative chemotherapy in breast cancer. J Clin Oncol 13:2712-2721, 1995
26. Early Breast Cancer Trialists Collaborative Groups: Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet 351:1451-1467, 1998
27. Kiang DT, Frenning DH, Goldman AI, et al: Estrogen receptors and responses to chemotherapy and hormonal therapy in advanced breast cancer. N Engl J Med 299:1330-1334, 1978
28. Lippman ME, Allegra JC: Lack of estrogen receptor associated with an increased response rate to cytotoxic chemotherapy in metastatic breast cancer? Recent Results Cancer Res 71:155-161, 1980
29. Goldie JH, Coldman AJ: A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 63:1727-1733, 1979
30. Fisher B, Gunduz N, Saffer EA: Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastasis. Cancer Res 43:1488-1492, 1983
31. Fisher B, Gunduz N, Coile J, et al: Presence of a growth-stimulating factor in serum following primary tumor removal in mice. Cancer Res 49:1996-2001, 1989
32. Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82:4-6, 1990
33. Hirata S, Matsubara T, Saura R, et al: Inhibition of in vitro vascular endothelial cell proliferation and in vivo neovascularisation by low dose methotrexate. Arthritis Rheum 32:1065-1073, 1989
34. Steiner R: Angiostatic activity of anticancer agents in the chick allantoic membrane (CHE-CAM) assay, in Steiner R, Weisz PB, Langer R (eds): Angiogenesis: Key Principles-Science-Technology-Medicine. Basel, Switzerland, Birkhaeuser Verlag, 1992, pp 449-454
35. Eggermont AMM, Steller EP, Sugarbaker PH: Laparotomy enhances intraperitoneal tumor growth and abrogates the antitumor effects of interleukin 2 and limphokine-activated killer cells. Surgery 102:71-78, 1987
36. Dickson RB, Lippman ME: Control of human breast cancer by estrogens, growth factors, and oncogenes, in Lippman ME, Dickson RB (eds): Breast Cancer: Cellular and Molecular Biology. Boston, MA, Kluwer Academic Publishers, 1988, pp 119-165
37. Pagani O, O'Neill A, Castiglione M, et al: Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: Results of The International Breast Cancer Study Group (IBCSG) Trial VI. Eur J Cancer 34:632-640, 1998
38. Fisher B, Bryant J, Wolmark N, et al: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16:2672-2685, 1998
39. Saccani Jotti G, Johnston SR, Salter J, et al: Comparison of new immunohistochemical assay for oestrogen receptor in paraffin wax embedded breast carcinoma tissue with quantitative enzyme immunoassay. J Clin Pathol 47:900-905, 1994
40. Alberts SR, Ingle JN, Roche PR, et al. Comparison of estrogen receptor determinations by a biochemical ligand-binding assay and immunohistochemical staining with monoclonal antibody ER1D5 in females with lymph node positive breast carcinoma entered on two prospective clinical trials. Cancer 78:764-772, 1996
41. Barnes DM, Harris WH, Smith P, et al: Immunohistochemical determination of oestrogen receptor: Comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients. Br J Cancer 74:1445-1451, 1996
42. Esteban JM, Ahn C, Battifora H, et al: Predictive value of estrogen receptors evaluated by quantitative immunohistochemical analysis in breast cancer. Am J Clin Pathol 102:9-12, 1994
43. International Breast Cancer Study Group: Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients. J Clin Oncol 15:1385-1394, 1997
44. Goldhirsch A, Coates AS, Colleoni M, et al: Adjuvant chemoendocrine therapy in postmenopausal breast cancer: Cyclophosphamide, methotrexate and fluorouracil dose and schedule may make a difference. J Clin Oncol 16:1358-1362, 1998